Monograph Details
|
|
Dermatological Disorders
> Warts
|
|
ALFERON N |
| Manufacturer |
|
Hemispherx Biopharma, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Interferon. |
| Generic Name |
|
Interferon alfa-n3 (human leukocyte derived) 5million IU/mL; inj; contains albumin (human). |
| Indications |
|
Refractory genital warts. |
| Children |
|
<18 yrs: not recommended. |
| Adults |
|
≥18yrs: 0.05mL (250,000 IU) injected into the base of each wart twice weekly; max 8 wks. Max dose per session: 0.5mL (2.5million IU). Wait 3 months before retreatment unless warts enlarge or new warts develop. |
| Contraindications |
|
Mouse immunoglobulin, egg protein, or neomycin allergy. |
| Precautions |
|
Cardiovascular or severe pulmonary disease. Coagulation or seizure disorders. Severe myelosuppression. Use effective contraception during treatment. Debilitated. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Adverse Reactions |
|
Flu-like symptoms. |
| How Supplied |
|
Vials (1mL)—1 |
|
|
|
|
